[go: up one dir, main page]

PL2509963T3 - Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli - Google Patents

Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli

Info

Publication number
PL2509963T3
PL2509963T3 PL10788479T PL10788479T PL2509963T3 PL 2509963 T3 PL2509963 T3 PL 2509963T3 PL 10788479 T PL10788479 T PL 10788479T PL 10788479 T PL10788479 T PL 10788479T PL 2509963 T3 PL2509963 T3 PL 2509963T3
Authority
PL
Poland
Prior art keywords
piperazin
phenylamino
pyrimidin
dimethoxy
dichloro
Prior art date
Application number
PL10788479T
Other languages
English (en)
Inventor
Joerg Berghausen
Prasad Koteswara Kapa
Joseph Mckenna
Joel Slade
Raeann Wu
Zhengming Du
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43983750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2509963(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2509963T3 publication Critical patent/PL2509963T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10788479T 2009-12-07 2010-12-06 Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli PL2509963T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26715509P 2009-12-07 2009-12-07
EP10788479.3A EP2509963B1 (en) 2009-12-07 2010-12-06 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.
PCT/US2010/059108 WO2011071821A1 (en) 2009-12-07 2010-12-06 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof.

Publications (1)

Publication Number Publication Date
PL2509963T3 true PL2509963T3 (pl) 2016-05-31

Family

ID=43983750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10788479T PL2509963T3 (pl) 2009-12-07 2010-12-06 Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli

Country Status (32)

Country Link
US (1) US9067896B2 (pl)
EP (1) EP2509963B1 (pl)
JP (2) JP5714024B2 (pl)
KR (1) KR101787784B1 (pl)
CN (5) CN102639510A (pl)
AR (2) AR079257A1 (pl)
AU (1) AU2010328391B2 (pl)
BR (1) BR112012013784B1 (pl)
CA (1) CA2781431C (pl)
CL (1) CL2012001480A1 (pl)
DK (1) DK2509963T3 (pl)
EC (1) ECSP12012026A (pl)
ES (1) ES2562462T3 (pl)
GT (1) GT201200181A (pl)
HR (1) HRP20160126T1 (pl)
HU (1) HUE026983T2 (pl)
IL (1) IL220012B (pl)
JO (1) JO3061B1 (pl)
MA (1) MA33849B1 (pl)
MX (1) MX2012006562A (pl)
MY (1) MY158333A (pl)
NZ (3) NZ600070A (pl)
PE (1) PE20121499A1 (pl)
PH (2) PH12012501146A1 (pl)
PL (1) PL2509963T3 (pl)
RU (1) RU2572848C2 (pl)
SG (1) SG10201408063SA (pl)
SI (1) SI2509963T1 (pl)
TN (1) TN2012000263A1 (pl)
TW (1) TWI526440B (pl)
WO (1) WO2011071821A1 (pl)
ZA (1) ZA201203612B (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RU2643326C2 (ru) * 2012-03-30 2018-01-31 Новартис Аг Ингибитор рецептора фрф для применения в лечении гипофосфатемических заболеваний
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CN110354128A (zh) * 2013-10-18 2019-10-22 卫材R&D管理有限公司 嘧啶fgfr4抑制剂
AU2014362999B2 (en) * 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
WO2016055916A1 (en) 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
CA2982562C (en) 2015-04-14 2023-06-13 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2016189472A1 (en) 2015-05-28 2016-12-01 Novartis Ag Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor
RU2730503C2 (ru) 2015-12-17 2020-08-24 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения рака молочной железы
JP7372740B2 (ja) 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
TWI669300B (zh) * 2016-05-20 2019-08-21 浙江海正藥業股份有限公司 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
IL264950B2 (en) * 2016-08-23 2024-01-01 Eisai R&D Man Co Ltd Combined treatments for the treatment of malignant liver cell carcinoma
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
JP7076565B2 (ja) 2017-11-01 2022-05-27 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ４阻害剤として用いられる化合物の塩形態、結晶形及びその製造方法
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI895290B (zh) * 2019-10-14 2025-09-01 大陸商和記黃埔醫藥（上海）有限公司 化合物的鹽及其晶型
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11583602B2 (en) 2021-06-23 2023-02-21 Kimtron, Inc. System and method for ultra-close proximity irradiation of rotating biomass
CN116768856A (zh) * 2022-03-18 2023-09-19 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
CN115785001B (zh) * 2022-11-23 2023-09-15 斯坦德药典标准物质研发(湖北)有限公司 一种英菲格拉替尼的制备方法
WO2024186882A1 (en) 2023-03-06 2024-09-12 Qed Therapeutics, Inc. Methods of treating skeletal dysplasias
WO2025061013A1 (zh) * 2023-09-18 2025-03-27 上海润石医药科技有限公司 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用
WO2025090870A1 (en) 2023-10-27 2025-05-01 Qed Therapeutics, Inc. Infigratinib and metabolites thereof for use in methods of treating skeletal disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101242843A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
ES2570994T3 (es) * 2005-11-08 2016-05-23 Choongwae Pharma Corp Miméticos de alfa-hélice y método relacionados con el tratamiento de células madre de cáncer
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
MX342553B (es) * 2008-04-29 2016-10-04 Novartis Ag Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas

Also Published As

Publication number Publication date
JP2013512956A (ja) 2013-04-18
CN111100078A (zh) 2020-05-05
MY158333A (en) 2016-09-30
AR114946A2 (es) 2020-11-11
CL2012001480A1 (es) 2014-09-05
CN105061332A (zh) 2015-11-18
HK1171016A1 (zh) 2013-03-15
GT201200181A (es) 2013-12-03
TW201144297A (en) 2011-12-16
ZA201203612B (en) 2013-01-30
CA2781431C (en) 2017-10-31
HUE026983T2 (en) 2016-08-29
DK2509963T3 (en) 2016-02-29
BR112012013784A8 (pt) 2017-12-26
MA33849B1 (fr) 2012-12-03
TWI526440B (zh) 2016-03-21
NZ624315A (en) 2014-11-28
SI2509963T1 (sl) 2016-05-31
NZ600070A (en) 2014-06-27
WO2011071821A1 (en) 2011-06-16
BR112012013784B1 (pt) 2021-11-03
BR112012013784A2 (pt) 2016-05-03
TN2012000263A1 (en) 2013-12-12
JP6019142B2 (ja) 2016-11-02
CN111100077A (zh) 2020-05-05
MX2012006562A (es) 2012-07-04
US9067896B2 (en) 2015-06-30
KR101787784B1 (ko) 2017-10-18
ECSP12012026A (es) 2012-08-31
JP2015107996A (ja) 2015-06-11
ES2562462T3 (es) 2016-03-04
PH12012501146A1 (en) 2012-10-22
NZ700778A (en) 2015-04-24
AU2010328391B2 (en) 2014-07-03
CN102639510A (zh) 2012-08-15
IL220012A0 (en) 2012-07-31
CA2781431A1 (en) 2011-06-16
KR20130028045A (ko) 2013-03-18
AR079257A1 (es) 2012-01-04
JP5714024B2 (ja) 2015-05-07
IL220012B (en) 2018-02-28
RU2012128351A (ru) 2014-01-20
EP2509963A1 (en) 2012-10-17
PH12014502593A1 (en) 2015-09-21
AU2010328391A1 (en) 2012-06-07
JO3061B1 (ar) 2017-03-15
RU2572848C2 (ru) 2016-01-20
HRP20160126T1 (hr) 2016-03-25
CN111269186A (zh) 2020-06-12
US20120245182A1 (en) 2012-09-27
SG10201408063SA (en) 2015-01-29
PE20121499A1 (es) 2012-11-15
EP2509963B1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
PL2509963T3 (pl) Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli
HUS000512I2 (hu) Larotrektinib és/vagy gyógyszerészetileg elfogadható sói, elõnyösen larotrektinib-szulfát, beleértve a larotrektinib-hidrogénszulfátot
AP2010005390A0 (en) Crystal form of phenylamino pyrimidine derivatives.
IL226474A (en) Crystalline forms of 5-chloro-n2- (2-isopropoxy-5-methyl-4-piperidene-4-aryl-phenyl) - n4 [2- (propane-2-sulfonyl) -phenyl] pyrimidine-4,2-diamine
SG10201401415QA (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
IL210176A0 (en) Substituted pyrimidone derivatives
EP2293754A4 (en) ABSORBENT ARTICLE OF PERSONAL GARMENT WITH A TAB
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
BRPI1014039A2 (pt) 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas
EP2139334A4 (en) CONDENSED HETEROCYCLIC 2-CYANOPHENYL COMPOUNDS AND COMPOSITIONS AND THEIR USE
ZA201100298B (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
PL2350026T3 (pl) Podstawione sulfoksyiminą pochodne anilinopirymidyny jako inhibitory CDK, ich wytwarzanie i zastosowanie jako lek
EP2288323A4 (en) ABSORBENT PERSONAL HYGIENE ARTICLE HAVING A SIZE ADJUSTMENT PAD
EP1951254A4 (en) [(2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL] -5-CHLORO-THIOPHENE-2-YL-SULFONYLUREES [4- (6-HALO-7-SUBSTITUTEES)] AND ASSOCIATED FORMS AND METHODS
EP2284160A4 (en) PYRIMIDINE DERIVATIVE HAVING CELL PROTECTIVE ACTIVITY AND USE THEREOF
IL201829A0 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
IL215483A0 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
ZA201201599B (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nico tinamide and salts thereof as hdl cholesterol raising agents
PL2376479T3 (pl) Podstawione furanokarboksyamidy i ich zastosowanie
Alp et al. Beslöjade avslöjanden: En kvalitativ undersökning med sex slöjbärande muslimska flickor
Batteate et al. Sustainable Living Lab
Riemsdijk et al. Lenition and Fortition
HK1166318A (en) Novel pyrimidine and triazine hepcidine antagonists
FI20075842A0 (fi) Kiteytetty laktaasi, menetelmä sen valmistamiseksi ja sen käyttö
SI2139334T1 (sl) Z 2-cianofenilom zlite hererociklične spojine in sestavki in njihova uporaba